C
Courtney Davis
Researcher at King's College London
Publications - 43
Citations - 1349
Courtney Davis is an academic researcher from King's College London. The author has contributed to research in topics: Pharmaceutical industry & Regulatory science. The author has an hindex of 17, co-authored 39 publications receiving 1093 citations. Previous affiliations of Courtney Davis include University of Sussex.
Papers
More filters
Journal ArticleDOI
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis,Huseyin Naci,Evrim Gurpinar,Elita Poplavska,Ashlyn Pinto,Ajay Aggarwal,Ajay Aggarwal +6 more
TL;DR: This systematic evaluation of oncology approvals by the EMA in 2009-13 shows that most drugs entered the market without evidence of benefit on survival or quality of life.
Journal ArticleDOI
Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
Huseyin Naci,Huseyin Naci,Courtney Davis,Jelena Savović,Jelena Savović,Julian P T Higgins,Julian P T Higgins,Julian P T Higgins,Jonathan A C Sterne,Jonathan A C Sterne,Bishal Gyawali,Bishal Gyawali,Xochitl Romo-Sandoval,Nicola Handley,Christopher M. Booth +14 more
TL;DR: Most pivotal studies forming the basis of EMA approval of new cancer drugs between 2014 and 2016 were randomised controlled trials, but almost half of these were judged to be at high risk of bias based on their design, conduct, or analysis, some of which might be unavoidable because of the complexity of cancer trials.
Journal ArticleDOI
Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund
TL;DR: The CDF has not delivered meaningful value to patients or society and there is no empirical evidence to support a ‘drug only’ ring fenced cancer fund relative to concomitant investments in other cancer domains such as surgery and radiotherapy, or other noncancer medicines.
Book
Unhealthy Pharmaceutical Regulation: Innovation, Politics and Promissory Science
Courtney Davis,John Abraham +1 more
TL;DR: This chapter discusses the political economy of 'Innovative' drug Regulation in the Neo-Liberal Era, and the Regulatory Science and Politics of Risk Management.
Journal ArticleDOI
A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.
John Abraham,Courtney Davis +1 more
TL;DR: It is concluded that the main explanation for fewer drug safety withdrawals in the US is that the regulatory agency there applied more stringent pre-market review and/or standards, which took longer than UK regulatory checks, but prevented unsafe drugs marketed in the UK from entering the US market.